Elacestrant for ER-positive, HER2-negative breast cancer with ctDNA relapse
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether elacestrant can help stop or delay breast cancer coming back in people whose blood test shows “ctDNA relapse” after early breast cancer treatment. It’s meant for hormone receptor–positive, HER2-negative breast cancer patients who are already taking hormone (endocrine) therapy and have no visible spread on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ER-positive and HER2-negative breast cancer (ER is positive on lab testing; HER2 is negative on lab testing).
- You are a woman (pre- or post-menopause) or a man age 18 or older with early breast cancer at higher risk of recurrence.
- You must be able to provide a usable tumor tissue sample for the ctDNA test (not a fine-needle aspirate).
- You must have had at least 1 year and up to 7.5 years of endocrine (ET) treatment and plan to continue it during the blood-test screening period.
- Your ctDNA blood test (Signatera, or an approved similar test) must come back positive, and scans must show no local/regional or metastatic disease.
- You need to be well enough for treatment (ECOG performance status 0–1) and meet basic organ-function and pregnancy-test requirements (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new hormone-blocking pill (elacestrant) with or without a shot that temporarily stops ovaries (triptorelin) for premenopausal women with early-stage, hormone-sensitive breast cancer. It aims to find a gentler treatment option before surgery.
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
Hear when a new ER Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.